LONDON (AP) — AstraZeneca says it intends to seek U.S. authorization for its COVID-19 vaccine in the “coming weeks,” acknowledging a delay in the the much-anticipated filing that had been expected by mid-April. The Anglo-Swedish drugmaker revealed the new timetable as it released first-quarter financial results, which showed that the company delivered 68 million doses of the vaccine to the U.K., European Union and other countries in the first quarter. The company said it was continuing to work on its application to the U.S. Food and Drug Administration. The White House says the U.S. will begin sharing its entire stock of AstraZeneca vaccines with the world once it clears federal safety reviews.
